Form 8-K Anthera Pharmaceuticals For: Mar 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Anthera Pharma (ANTH) Tops Q4 EPS by 10c
March 10, 2016 8:38 AM ESTAnthera Pharma (NASDAQ: ANTH) reported Q4 EPS of ($0.18), $0.10 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $1.92 million versus the consensus estimate of $150 thousand.
Cash and cash equivalents totaled $47 million as of December 31, 2015, compared to $2.6 million as of December 31,... More
